Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gastric Cancer
  Free Subscription

Articles published in
Gut
    April 2024
  1. ZHANG F, Sahu V, Peng K, Wang Y, et al
    Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.
    Gut. 2024 Apr 15:gutjnl-2023-329686. doi: 10.1136/gutjnl-2023-329686.
    >> Share

    February 2024
  2. RUGGE M, Genta RM, Malfertheiner P, Dinis-Ribeiro M, et al
    RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates.
    Gut. 2024;73:407-441.
    >> Share

    January 2024
  3. TAKEUCHI C, Yamashita S, Liu YY, Takeshima H, et al
    Precancerous nature of intestinal metaplasia with increased chance of conversion and accelerated DNA methylation.
    Gut. 2024;73:255-267.
    >> Share

    December 2023
  4. LATORRE G, Silva F, Montero I, Bustamante M, et al
    Comparison of OLGA and OLGIM as predictors of gastric cancer in a Latin American population: the ECHOS Study.
    Gut. 2023 Dec 26:gutjnl-2023-331059. doi: 10.1136/gutjnl-2023-331059.
    >> Share

  5. MORAIS R, Libanio D, Dinis Ribeiro M, Ferreira A, et al
    Predicting residual neoplasia after a non-curative gastric ESD: validation and modification of the eCura system in the Western setting: the W-eCura score.
    Gut. 2023;73:105-117.
    >> Share

  6. TAN P, Chu Y
    Single-cell profiling of gastric cardia adenocarcinoma reveals drivers of cancer stemness and therapeutic targets.
    Gut. 2023;73:1-2.
    >> Share

  7. WANG Z, Wang Q, Chen C, Zhao X, et al
    NNMT enriches for AQP5(+) cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma.
    Gut. 2023;73:63-77.
    >> Share

    November 2023
  8. LAHNER E, Dilaghi E, Dottori L, Annibale B, et al
    Not all that is corpus restricted is necessarily autoimmune.
    Gut. 2023;72:2384-2385.
    >> Share

    August 2023
  9. LEJA M
    Potential of personalised approaches in gastric cancer prevention.
    Gut. 2023 Aug 27:gutjnl-2023-330215. doi: 10.1136/gutjnl-2023-330215.
    >> Share

    July 2023
  10. XU Z, Huang Y, Hu C, Du L, et al
    Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study.
    Gut. 2023 Jul 17:gutjnl-2023-330045. doi: 10.1136/gutjnl-2023-330045.
    >> Share

  11. CAO LL, Lu H, Soutto M, Bhat N, et al
    Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-gamma signalling.
    Gut. 2023 Jul 4:gutjnl-2022-329134. doi: 10.1136/gutjnl-2022-329134.
    >> Share

    May 2023
  12. LEI WY, Lee JY, Chuang SL, Bair MJ, et al
    Eradicating Helicobacter pylori via (13)C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method.
    Gut. 2023 May 17:gutjnl-2023-329871. doi: 10.1136/gutjnl-2023-329871.
    >> Share

    April 2023
  13. RALSER A, Dietl A, Jarosch S, Engelsberger V, et al
    Helicobacter pylori promotes colorectal carcinogenesis by deregulating intestinal immunity and inducing a mucus-degrading microbiota signature.
    Gut. 2023 Apr 4:gutjnl-2022-328075. doi: 10.1136/gutjnl-2022-328075.
    >> Share

  14. FAN Y, Li Y, Yao X, Jin J, et al
    Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment.
    Gut. 2023;72:624-637.
    >> Share

    March 2023
  15. XU C, Huang KK, Law JH, Chua JS, et al
    Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities.
    Gut. 2023 Mar 14:gutjnl-2022-328332. doi: 10.1136/gutjnl-2022-328332.
    >> Share

    February 2023
  16. RUGGE M, Genta RM, Malfertheiner P, Graham DY, et al
    Gastric cancer risk in autoimmune gastritis: evidence versus opinion.
    Gut. 2023 Feb 27:gutjnl-2023-329618. doi: 10.1136/gutjnl-2023-329618.
    >> Share

    January 2023
  17. WALDUM HL
    Conclusion that autoimmune gastritis does not predispose to gastric cancer is unproven.
    Gut. 2023 Jan 24:gutjnl-2022-329323. doi: 10.1136/gutjnl-2022-329323.
    >> Share

  18. GOLDENRING J
    No H. pylori, no adenocarcinoma for patients with autoimmune gastritis.
    Gut. 2023;72:1-2.
    >> Share

    October 2022
  19. LI M, Park JY, Sheikh M, Kayamba V, et al
    Population-based investigation of common and deviating patterns of gastric cancer and oesophageal cancer incidence across populations and time.
    Gut. 2022 Oct 14. pii: gutjnl-2022-328233. doi: 10.1136/gutjnl-2022-328233.
    >> Share

    September 2022
  20. RUGGE M, Genta RM, Malfertheiner P, Graham DY, et al
    Steps forward in understanding gastric cancer risk.
    Gut. 2022 Sep 16. pii: gutjnl-2022-328514. doi: 10.1136/gutjnl-2022-328514.
    >> Share

    August 2022
  21. LENTI MV, Broglio G, Di Sabatino A
    Unravelling the risk of developing gastric cancer in autoimmune gastritis.
    Gut. 2022 Aug 18. pii: gutjnl-2022-328345. doi: 10.1136/gutjnl-2022-328345.
    >> Share

  22. DAWSON RE, Deswaerte V, West AC, Tang K, et al
    STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis.
    Gut. 2022;71:1515-1531.
    >> Share

    July 2022
  23. WANG Z, Han W, Xue F, Zhao Y, et al
    Nationwide gastric cancer prevention in China, 2021-2035: a decision analysis on effect, affordability and cost-effectiveness optimisation.
    Gut. 2022 Jul 28. pii: gutjnl-2021-325948. doi: 10.1136/gutjnl-2021-325948.
    >> Share

  24. HO SWT, Sheng T, Xing M, Ooi WF, et al
    Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities.
    Gut. 2022 Jul 11. pii: gutjnl-2021-326483. doi: 10.1136/gutjnl-2021-326483.
    >> Share

  25. BROWN JW
    Gut check: can other microbes or communities phenocopy H. pylori's early gastric pathology?
    Gut. 2022;71:1241-1242.
    >> Share

  26. SUNDAR R, Huang KK, Kumar V, Ramnarayanan K, et al
    Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
    Gut. 2022;71:1277-1288.
    >> Share

  27. KWON SK, Park JC, Kim KH, Yoon J, et al
    Human gastric microbiota transplantation recapitulates premalignant lesions in germ-free mice.
    Gut. 2022;71:1266-1276.
    >> Share

    June 2022
  28. RUGGE M, Bricca L, Guzzinati S, Sacchi D, et al
    Autoimmune gastritis: long-term natural history in naive Helicobacter pylori-negative patients.
    Gut. 2022 Jun 30. pii: gutjnl-2022-327827. doi: 10.1136/gutjnl-2022-327827.
    >> Share

  29. TONG Y, Cheng PSW, Or CS, Yue SSK, et al
    Escape from cell-cell and cell-matrix adhesion dependence underscores disease progression in gastric cancer organoid models.
    Gut. 2022 Jun 15. pii: gutjnl-2022-327121. doi: 10.1136/gutjnl-2022-327121.
    >> Share

  30. CALDWELL B, Meyer AR, Weis JA, Engevik AC, et al
    Chief cell plasticity is the origin of metaplasia following acute injury in the stomach mucosa.
    Gut. 2022;71:1068-1077.
    >> Share

    April 2022
  31. QUANTE M, Wang TC, Bass AJ
    Adenocarcinoma of the oesophagus: is it gastric cancer?
    Gut. 2022 Apr 1. pii: gutjnl-2022-327096. doi: 10.1136/gutjnl-2022-327096.
    >> Share

    March 2022
  32. DONG X, Song S, Li Y, Fan Y, et al
    Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency.
    Gut. 2022;71:467-478.
    >> Share

    December 2021
  33. SONG S, Chen Q, Li Y, Lei G, et al
    Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma.
    Gut. 2021;70:2238-2248.
    >> Share

    November 2021
  34. ZENG R, Sha W, Wang J, Zhuo Z, et al
    Evaluation of proton pump inhibitors and risks of gastric cancer.
    Gut. 2021 Nov 26. pii: gutjnl-2021-326291. doi: 10.1136/gutjnl-2021-326291.
    >> Share

  35. ARNOLD M, Morgan E, Bardot A, Rutherford MJ, et al
    International variation in oesophageal and gastric cancer survival 2012-2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study).
    Gut. 2021 Nov 25. pii: gutjnl-2021-325266. doi: 10.1136/gutjnl-2021-325266.
    >> Share

  36. LIU X, Chen T, Cheng J, Gao P, et al
    Endoscopic transmural route for dissection of gastric submucosal tumors with extraluminal growth: experience in two cases.
    Gut. 2021;70:2052-2054.
    >> Share

  37. HAO D, He S, Harada K, Pizzi MP, et al
    Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma.
    Gut. 2021;70:2055-2065.
    >> Share

    October 2021
  38. MATSUO J, Douchi D, Myint K, Mon NN, et al
    Iqgap3-Ras axis drives stem cell proliferation in the stomach corpus during homoeostasis and repair.
    Gut. 2021;70:1833-1846.
    >> Share

    September 2021
  39. RINKE A, Auernhammer CJ, Bodei L, Kidd M, et al
    Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?
    Gut. 2021;70:1768-1781.
    >> Share

  40. SMYTH EC, Vlachogiannis G, Hedayat S, Harbery A, et al
    EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
    Gut. 2021;70:1632-1641.
    >> Share

    August 2021
  41. ARAI J, Niikura R, Hayakawa Y, Aoki T, et al
    OLGIM staging and proton pump inhibitor use predict the risk of gastric cancer.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325551. doi: 10.1136/gutjnl-2021-325551.
    >> Share

    July 2021
  42. PATEL J, Berezowski I, Janapala RN, Pourmand A, et al
    Proton pump inhibitors and gastric cancer: a population-based cohort study.
    Gut. 2021 Jul 14. pii: gutjnl-2021-325385. doi: 10.1136/gutjnl-2021-325385.
    >> Share

  43. ABRAHAMI D, McDonald EG, Schnitzer ME, Barkun AN, et al
    Proton pump inhibitors and risk of gastric cancer: population-based cohort study.
    Gut. 2021 Jul 5. pii: gutjnl-2021-325097. doi: 10.1136/gutjnl-2021-325097.
    >> Share

  44. YAMAO K, Kitano M, Chiba Y, Ogura T, et al
    Endoscopic placement of covered versus uncovered self-expandable metal stents for palliation of malignant gastric outlet obstruction.
    Gut. 2021;70:1244-1252.
    >> Share

    May 2021
  45. SUNDAR R, Barr Kumarakulasinghe N, Huak Chan Y, Yoshida K, et al
    Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.
    Gut. 2021 May 12. pii: gutjnl-2021-324060. doi: 10.1136/gutjnl-2021-324060.
    >> Share

  46. SEO SI, Park CH, You SC, Kim JY, et al
    Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
    Gut. 2021 May 11. pii: gutjnl-2020-323845. doi: 10.1136/gutjnl-2020-323845.
    >> Share

  47. LEE JWJ, Zhu F, Srivastava S, Tsao SK, et al
    Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP).
    Gut. 2021 May 11. pii: gutjnl-2021-324057. doi: 10.1136/gutjnl-2021-324057.
    >> Share

    March 2021
  48. LO CH, Kwon S, Wang L, Polychronidis G, et al
    Periodontal disease, tooth loss, and risk of oesophageal and gastric adenocarcinoma: a prospective study.
    Gut. 2021;70:620-621.
    >> Share

  49. ZHANG M, Hu S, Min M, Ni Y, et al
    Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing.
    Gut. 2021;70:464-475.
    >> Share

    February 2021
  50. BEALES ILP
    Gastric biopsies in the assessment and management of patients at risk of gastric adenocarcinoma.
    Gut. 2021;70:431-432.
    >> Share

  51. CHEN R, Liu Y, Song G, Li B, et al
    Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study.
    Gut. 2021;70:251-260.
    >> Share

  52. TAKENAKA K, Kimura M, Ohtsuka K
    Colonic strictures mimicking Crohn's disease.
    Gut. 2021;70:233-387.
    >> Share

    January 2021
  53. AJANI JA, Xu Y, Huo L, Wang R, et al
    YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition.
    Gut. 2021;70:55-66.
    >> Share

    November 2020
  54. SUNDAR R, Liu DH, Hutchins GG, Slaney HL, et al
    Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination.
    Gut. 2020 Nov 23. pii: gutjnl-2020-320805. doi: 10.1136/gutjnl-2020-320805.
    >> Share

    October 2020
  55. SO JBY, Kapoor R, Zhu F, Koh C, et al
    Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population.
    Gut. 2020 Oct 7. pii: gutjnl-2020-322065. doi: 10.1136/gutjnl-2020-322065.
    >> Share

  56. LIOU JM, Malfertheiner P, Lee YC, Sheu BS, et al
    Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus.
    Gut. 2020 Oct 1. pii: gutjnl-2020-322368. doi: 10.1136/gutjnl-2020-322368.
    >> Share

  57. MARCOS P, Brito-Goncalves G, Libanio D, Pita I, et al
    Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West?
    Gut. 2020;69:1762-1768.
    >> Share

  58. KRISHNAN V, Lim DXE, Hoang PM, Srivastava S, et al
    DNA damage signalling as an anti-cancer barrier in gastric intestinal metaplasia.
    Gut. 2020;69:1738-1749.
    >> Share

    September 2020
  59. BANKS M, Uedo N, Bhandari P, Gotoda T, et al
    EMR achieves similar oncological outcomes as ESD for gastric neoplasia of <1cm, requiring less expertise, training and time.
    Gut. 2020;69:1.
    >> Share

  60. SHAHIDI N, Bourke MJ
    ESD, not EMR, should be the first-line therapy for early gastric neoplasia.
    Gut. 2020;69:1-2.
    >> Share

  61. GHISA M, Rugge M, Fassan M, Farinati F, et al
    There is much more to rely on histology than the sole endoscopy tells us.
    Gut. 2020;69:1.
    >> Share

    June 2020
  62. OOI WF, Nargund AM, Lim KJ, Zhang S, et al
    Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma.
    Gut. 2020;69:1039-1052.
    >> Share

    April 2020
  63. XIONG J, Wang Y, Chen G, Jin L, et al
    Proton pump inhibitors and the risk of gallbladder cancer: a hospital-based case-control study.
    Gut. 2020 Apr 9. pii: gutjnl-2020-321052. doi: 10.1136/gutjnl-2020-321052.
    >> Share

    May 2019
  64. DOORAKKERS E, Lagergren J, Engstrand L, Brusselaers N, et al
    Reply to: Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a western population.
    Gut. 2019 May 21. pii: gutjnl-2019-319000. doi: 10.1136/gutjnl-2019-319000.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016